Welcome to E-Menai

alcohol ambien Cambia, formulated with KPA's patented Dynamic Buffering Technology (DBT), was specifically developed to address widespread unmet needs among patients by offering fast and effective relief of migraine pain." KPA obtained exclusive U. Kowa's pharmaceutical division is focused on cardiovascular therapeutics, with fiscal year 2008 sales of the company's flagship product, LIVALO® (pitavastatin) totaling . is a specialty pharmaceutical company focused primarily in the area of cardiology. Other alcohol ambien important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of each of the Companies' Annual Reports on Form 10-K for the year ended December 31, 2008 and their respective Quarterly Reports on Form 10-Q for the quarter ended March 31, 2009, each of which is on file with the U.